HIV-associated neurocognitive disorders (HAND) encompass a spectrum of cognitive, behavioral, and motor impairments seen in people with HIV, ranging from asymptomatic neurocognitive impairment to mild and more severe forms of HIV-associated dementia. Although modern antiretroviral therapy (ART) has substantially reduced the prevalence of advanced dementia, HAND persists in clinical practice—particularly as the treated population ages and accumulates comorbid vascular, metabolic, and inflammatory conditions. HAND is best understood as a multifactorial neuroinflammatory and neurodegenerative process driven by ongoing viral or immune activation, blood–brain barrier dysfunction, and secondary injury from systemic comorbidities.
Clinically, HAND is typically identified through a combination of symptom history, collateral informant reports, functional assessment, and formal neuropsychological testing. Screening is essential because cognitive deficits may be subtle, fluctuating, and underreported, especially when individuals attribute symptoms to “normal aging.” In aging adults with HIV, the threshold for evaluation should be lower: early impairments can affect medication adherence, driving safety, and independent living. Neurocognitive screening tools and brief batteries are used to detect patterns suggestive of HAND, followed by comprehensive testing when indicated. A core principle is domain-based assessment—memory, attention, processing speed, executive function, and motor skills—because HAND may present with relatively specific cognitive inefficiencies rather than a single global decline.
Mechanistically, HAND reflects the convergence of HIV-related and host-related factors. Incomplete viral suppression or residual low-level replication can sustain immune activation within the central nervous system. Microglial activation and cytokine signaling contribute to synaptic dysfunction and neuronal injury. Concurrently, cerebrovascular disease risk rises with age and with traditional factors such as hypertension, dyslipidemia, diabetes, smoking, and chronic kidney disease. These vascular contributions accelerate cognitive decline through small-vessel ischemia and impaired cerebral perfusion. In parallel, chronic ART exposure can shape metabolic risk, altering cardiovascular and inflammatory pathways that secondarily impact the brain.
Frailty is increasingly recognized as a clinically relevant bridge between systemic aging biology and neurocognitive outcomes. Frail individuals have reduced physiologic reserve, higher rates of falls, polypharmacy, malnutrition, and inflammation. Such conditions can exacerbate cognitive vulnerability by promoting sarcopenia, sleep disruption, and medication adverse effects. Moreover, frailty and cognitive impairment can form a bidirectional cycle: cognitive deficits impair self-care and nutrition, while physical decline restricts activity and worsens vascular risk. For clinicians, integrated assessment of cognition and frailty supports more accurate prognostication and individualized care planning.
Management of HAND is primarily preventive and optimization-oriented. The first step is ensuring sustained virologic suppression with ART regimens selected to minimize drug–drug interactions and adverse metabolic or neurologic effects. Avoiding clinically meaningful interactions is particularly important in older adults receiving polypharmacy for comorbidities such as hyperlipidemia, cardiovascular disease, mood disorders, and pain. Addressing vascular risk factors is a major evidence-informed strategy: controlling blood pressure, improving glycemic status, treating dyslipidemia, promoting smoking cessation, and encouraging structured exercise all reduce downstream neurovascular injury. In some contexts, lipid-lowering therapy is used to lower cardiovascular and potentially neuroinflammatory risk; selection may depend on ART compatibility.
Cognitive symptoms also benefit from targeted supportive interventions. Medication simplification, adherence aids (pill organizers, reminders, supervised dosing when needed), and occupational or cognitive rehabilitation strategies can mitigate functional impact. Sleep evaluation is important because insomnia and sleep apnea are associated with impaired cognition and worsened inflammation. Treating depression and anxiety is critical as well; mood disorders can mimic cognitive impairment (“pseudodementia”) and amplify attention and executive dysfunction. When present, neurologic comorbidities—such as stroke, neuropathy, or degenerative diseases—should be identified because they alter both prognosis and treatment.
Screening and follow-up require longitudinal clinical reasoning. HAND evaluation should be revisited after ART changes, during episodes of intercurrent illness, and as comorbidities progress. Clinicians should also monitor for medication toxicity and central nervous system side effects. Because HAND is heterogeneous, a “one-size-fits-all” approach is less effective than an integrated model that treats HIV suppression, immune activation risks, vascular comorbidity, frailty, mental health, and functional supports as a unified care pathway.
For patients and caregivers, education can reduce stigma and improve engagement with evaluation. Explaining that cognitive change is not inevitable with aging—and that HAND can be detected and managed—encourages timely assessment and adherence. Ultimately, aging with HIV requires proactive neurocognitive surveillance, systematic frailty-informed care, and risk-factor modification. Source: [disclosurehiv] Source: Kristine Erlandson, MD’s guidance on frailty, HAND screening, and comorbidity management in people aging with HIV. Source: disclosurehiv
HIVDisclosureProject: Aging With HIV: Managing Comorbidities in a Population That Has Outlived Its Prognosis Why people with HIV age faster: Kristine Erlandson, MD, offers expert tips on frailty, HAND screening, statins post-REPRIEVE, and avoiding ART drug interactions.. #breaking
— @disclosurehiv May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
